Two decades of hepatitis B vaccination in mentally retarded patients: effectiveness, antibody persistence and duration of immune memory

Vaccine. 2012 Jul 6;30(32):4757-61. doi: 10.1016/j.vaccine.2012.05.044. Epub 2012 May 29.

Abstract

Introduction: Institutionalized mentally retarded subjects are well-known to be at-risk for HBV infection. We studied the persistence of vaccine-induced anti-HBs antibodies and the robustness of the HBsAg-specific immune memory in this population, 18-20 years after the first vaccine dose.

Materials and methods: Non-immune residents of 4 institutions were immunized in 1984-1986. In 2004, 207 subjects were bled to determine humoral and cellular immune memory. Immune response to a booster dose was evaluated in subjects with anti-HBs level <100 IU/L.

Results: Four subjects showed anti-HBc seroconversion, without clinical implications. Pre-booster anti-HBs levels <100 IU/L were found in 45 subjects (22%); 34/39 (87%) responded with a rapid and high anti-HBs titer to the booster dose. Robust T and B cell memory was present pre- and post-booster.

Discussion and conclusion: Overall results confirm that hepatitis B vaccines are highly effective and immunogenic, and confer long-term persistence of antibodies and immune memory in an at-risk population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • B-Lymphocytes / immunology
  • Female
  • Hepatitis B Antibodies / blood*
  • Hepatitis B Vaccines / administration & dosage*
  • Humans
  • Immunity, Cellular
  • Immunization, Secondary
  • Immunologic Memory*
  • Institutionalization
  • Male
  • Middle Aged
  • Persons with Intellectual Disabilities / statistics & numerical data*
  • T-Lymphocytes / immunology
  • Young Adult

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Vaccines